Weiss Ratings Reiterates "Sell (D-)" Rating for Annexon (NASDAQ:ANNX)

Key Points

• Weiss Ratings has reiterated a "Sell (D-)" rating for Annexon (NASDAQ:ANNX) in a recent research note issued to investors.
• Despite Weiss's negative stance, other analysts have mixed ratings on the stock, with HC Wainwright giving a "Buy" rating and a $14.00 target price.
• Annexon recently reported earnings per share of ($0.34), beating consensus estimates, while its stock is currently trading at $3.21.

Annexon (NASDAQ:ANNX - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

Other equities analysts have also issued research reports about the company. HC Wainwright reissued a "buy" rating and issued a $14.00 target price on shares of Annexon in a research note on Friday, August 15th. Zacks Research raised Annexon from a "strong sell" rating to a "hold" rating in a research report on Monday, August 18th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Annexon has an average rating of "Hold" and a consensus price target of $12.50.

Annexon Stock Performance

NASDAQ:ANNX traded up $0.16 during mid-day trading on Friday, hitting $3.21. The company had a trading volume of 3,193,160 shares, compared to its average volume of 1,642,270. Annexon has a fifty-two week low of $1.28 and a fifty-two week high of $7.64. The business's fifty day moving average is $2.67 and its two-hundred day moving average is $2.35. The firm has a market cap of $352.75 million, a P/E ratio of -2.49 and a beta of 1.36.

Annexon (NASDAQ:ANNX - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.02. Equities analysts forecast that Annexon will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Nuveen LLC bought a new position in Annexon in the first quarter valued at approximately $670,000. Wellington Management Group LLP grew its stake in Annexon by 32.9% in the first quarter. Wellington Management Group LLP now owns 356,480 shares of the company's stock valued at $688,000 after purchasing an additional 88,314 shares in the last quarter. J. Safra Sarasin Holding AG grew its stake in Annexon by 49.9% in the second quarter. J. Safra Sarasin Holding AG now owns 381,441 shares of the company's stock valued at $915,000 after purchasing an additional 126,903 shares in the last quarter. XTX Topco Ltd grew its stake in Annexon by 65.4% in the first quarter. XTX Topco Ltd now owns 58,130 shares of the company's stock valued at $112,000 after purchasing an additional 22,979 shares in the last quarter. Finally, Matauro LLC bought a new position in Annexon in the second quarter valued at approximately $27,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.